4
Changes in Ownership
Dyne Therapeutics, Inc. Filed Acc 0000950170-24-030479
CEO & President sold 429,730 shares at an average $25.89 ($11,125,776)
- CEO & President acquired 413,343 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Brumm Joshua T CEO & President | 2024-03-08 | Option exercise 10b5-1 | +153,931 | $5.54 | $852,778 | 708,316 | D |
| Brumm Joshua T CEO & President | 2024-03-08 | Option exercise 10b5-1 | +209,412 | $5.54 | $1,160,142 | 917,728 | D |
| Brumm Joshua T CEO & President | 2024-03-08 | Sale 10b5-1 | −202,238 | $25.30 | $5,116,621 | 715,490 | D |
| Brumm Joshua T CEO & President | 2024-03-08 | Sale 10b5-1 | −160,670 | $26.72 | $4,293,102 | 554,820 | D |
| Brumm Joshua T CEO & President | 2024-03-08 | Sale 10b5-1 | −435 | $27.38 | $11,910 | 554,385 | D |
| Brumm Joshua T CEO & President | 2024-03-11 | Option exercise 10b5-1 | +50,000 | $5.54 | $277,000 | 604,385 | D |
| Brumm Joshua T CEO & President | 2024-03-11 | Sale 10b5-1 | −40,072 | $25.42 | $1,018,630 | 564,313 | D |
| Brumm Joshua T CEO & President | 2024-03-11 | Sale 10b5-1 | −9,928 | $26.10 | $259,121 | 554,385 | D |
| Brumm Joshua T CEO & President | 2024-03-11 | Sale 10b5-1 | −7,769 | $26.12 | $202,926 | 546,616 | D |
| Brumm Joshua T CEO & President | 2024-03-11 | Sale 10b5-1 | −8,618 | $25.93 | $223,465 | 537,998 | D |
| Derivatives | |||||||
| Brumm Joshua T CEO & President | 2024-03-08 | Option exercise · Stock option (right to buy) 10b5-1 | −153,931 | 0 | D | ||
| Brumm Joshua T CEO & President | 2024-03-08 | Option exercise · Stock option (right to buy) 10b5-1 | −209,412 | 133,269 | D | ||
| Brumm Joshua T CEO & President | 2024-03-11 | Option exercise · Stock option (right to buy) 10b5-1 | −50,000 | 83,269 | D | ||
| Open-market sales · 429,730 sh · avg $25.89 · $11,125,776 | |||||||
Loading xslF345X05/ownership.xml…